DELAWARE
(State
of Incorporation)
|
13-5315170
(I.R.S.
Employer Identification
No.)
|
YES
|
X
|
NO
|
|
YES
|
|
NO
|
|
Large
Accelerated filer
|
X
|
Accelerated
filer
|
|
Non-accelerated
filer
|
|
Smaller
reporting company
|
|
YES
|
|
NO
|
X
|
Page
|
|
|
|
|
|
3
|
|
|
|
4
|
|
|
|
5
|
|
|
|
6
|
|
|
|
21
|
|
|
|
22
|
|
|
|
51
|
|
|
|
51
|
|
|
|
|
|
52
|
|
|
|
54
|
|
|
|
55
|
|
|
|
55
|
|
|
|
55
|
|
|
|
57
|
|
|
|
57
|
|
|
|
58
|
Three
Months Ended
|
||||||||
(millions,
except per common share data)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||
Revenues
|
$ | 10,867 | $ | 11,848 | ||||
Costs
and expenses:
|
||||||||
Cost of sales(a)
|
1,408 | 1,986 | ||||||
Selling, informational and
administrative expenses(a)
|
2,876 | 3,492 | ||||||
Research and development
expenses(a)
|
1,705 | 1,791 | ||||||
Amortization of intangible
assets
|
578 | 779 | ||||||
Acquisition-related in-process
research and development charges
|
– | 398 | ||||||
Restructuring charges and
acquisition-related costs
|
554 | 178 | ||||||
Other (income)/deductions –
net
|
(57 | ) | (333 | ) | ||||
Income
from continuing operations before provision for taxes on
income
|
3,803 | 3,557 | ||||||
Provision
for taxes on income
|
1,074 | 763 | ||||||
Income
from continuing operations
|
2,729 | 2,794 | ||||||
Discontinued
operations - net of tax
|
1 | (4 | ) | |||||
Net
income before allocation to noncontrolling interests
|
2,730 | 2,790 | ||||||
Less: Net
income attributable to noncontrolling interests
|
1 | 6 | ||||||
Net
income attributable to Pfizer Inc.
|
$ | 2,729 | $ | 2,784 | ||||
Earnings
per share – basic:
|
||||||||
Income from continuing operations
attributable to Pfizer Inc. common shareholders
|
$ | 0.41 | $ | 0.41 | ||||
Discontinued operations - net of
tax
|
– | – | ||||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 0.41 | $ | 0.41 | ||||
Earnings
per share – diluted:
|
||||||||
Income from continuing operations
attributable to Pfizer Inc. common shareholders
|
$ | 0.40 | $ | 0.41 | ||||
Discontinued operations - net of
tax
|
– | – | ||||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 0.40 | $ | 0.41 | ||||
Weighted-average
shares used to calculate earnings per common share:
|
||||||||
Basic
|
6,723 | 6,739 | ||||||
Diluted
|
6,753 | 6,762 | ||||||
Cash
dividends paid per common share
|
$ | 0.32 | $ | 0.32 |
(a)
Exclusive of amortization of intangible assets, except as disclosed in
Note 10B. Goodwill and
Other Intangible Assets:Other Intangible
Assets.
|
(millions
of dollars)
|
Mar. 29,
2009*
|
Dec. 31,
2008**
|
||||||
ASSETS
|
||||||||
Cash
and cash equivalents
|
$ | 1,247 | $ | 2,122 | ||||
Short-term
investments
|
32,805 | 21,609 | ||||||
Accounts
receivable, less allowance for doubtful accounts
|
9,596 | 8,958 | ||||||
Short-term
loans
|
793 | 824 | ||||||
Inventories
|
4,458 | 4,381 | ||||||
Taxes
and other current assets
|
5,055 | 5,034 | ||||||
Assets
held for sale
|
299 | 148 | ||||||
Total current
assets
|
54,253 | 43,076 | ||||||
Long-term
investments and loans
|
13,536 | 11,478 | ||||||
Property,
plant and equipment, less accumulated depreciation
|
12,936 | 13,287 | ||||||
Goodwill
|
21,482 | 21,464 | ||||||
Identifiable
intangible assets, less accumulated amortization
|
16,923 | 17,721 | ||||||
Other
assets, deferred taxes and deferred charges
|
3,802 | 4,122 | ||||||
Total
assets
|
$ | 122,932 | $ | 111,148 | ||||
LIABILITIES AND SHAREHOLDERS’
EQUITY
|
||||||||
Short-term
borrowings, including current portion of long-term debt
|
$ | 7,613 | $ | 9,320 | ||||
Accounts
payable
|
1,573 | 1,751 | ||||||
Dividends
payable
|
1 | 2,159 | ||||||
Income
taxes payable
|
542 | 656 | ||||||
Accrued
compensation and related items
|
1,565 | 1,667 | ||||||
Other
current liabilities
|
12,046 | 11,456 | ||||||
Total current
liabilities
|
23,340 | 27,009 | ||||||
Long-term
debt
|
21,064 | 7,963 | ||||||
Pension
benefit
obligations
|
4,038 | 4,235 | ||||||
Postretirement
benefit obligations
|
1,604 | 1,604 | ||||||
Deferred
taxes
|
2,849 | 2,959 | ||||||
Other
taxes payable
|
6,770 | 6,568 | ||||||
Other
noncurrent liabilities
|
2,826 | 3,070 | ||||||
Total
liabilities
|
62,491 | 53,408 | ||||||
Preferred
stock
|
69 | 73 | ||||||
Common
stock
|
443 | 443 | ||||||
Additional
paid-in capital
|
70,201 | 70,283 | ||||||
Employee
benefit trust, at fair
value
|
(285 | ) | (425 | ) | ||||
Treasury
stock
|
(57,363 | ) | (57,391 | ) | ||||
Retained
earnings
|
51,863 | 49,142 | ||||||
Accumulated
other comprehensive expense
|
(4,673 | ) | (4,569 | ) | ||||
Total Pfizer Inc. shareholders’
equity
|
60,255 | 57,556 | ||||||
Equity
attributable to noncontrolling interests
|
186 | 184 | ||||||
Total shareholders’
equity
|
60,441 | 57,740 | ||||||
Total liabilities and
shareholders’ equity
|
$ | 122,932 | $ | 111,148 |
* | Unaudited. |
** | Condensed from audited financial statements. |
Three
Months Ended
|
||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||
Operating Activities:
|
||||||||
Net
income before allocation to noncontrolling
interests
|
$ | 2,730 | $ | 2,790 | ||||
Adjustments
to reconcile net income before allocation to noncontrolling interests to
net
cash
provided by operating activities:
|
||||||||
Depreciation and
amortization
|
1,008 | 1,487 | ||||||
Share-based compensation
expense
|
71 | 101 | ||||||
Acquisition-related in-process
research and development charges
|
– | 398 | ||||||
Deferred taxes from continuing
operations
|
533 | 544 | ||||||
Other non-cash
adjustments
|
(296 | ) | 213 | |||||
Changes in assets and
liabilities (net of businesses acquired and divested)
|
(899 | ) | (2,262 | ) | ||||
Net
cash provided by operating activities
|
3,147 | 3,271 | ||||||
Investing Activities:
|
||||||||
Purchases
of property, plant and equipment
|
(253 | ) | (483 | ) | ||||
Purchases
of short-term investments
|
(17,724 | ) | (10,648 | ) | ||||
Proceeds
from redemptions and sales of short-term investments
|
6,711 | 6,817 | ||||||
Purchases
of long-term investments
|
(3,442 | ) | (498 | ) | ||||
Proceeds
from redemptions and sales of long-term investments
|
889 | 42 | ||||||
Acquisitions,
net of cash acquired
|
– | (610 | ) | |||||
Other
|
185 | (104 | ) | |||||
Net
cash used in investing activities
|
(13,634 | ) | (5,484 | ) | ||||
Financing Activities:
|
||||||||
Increase
in short-term borrowings, net
|
10,774 | 4,899 | ||||||
Principal
payments on short-term borrowings
|
(12,100 | ) | (1,955 | ) | ||||
Proceeds
from issuances of long-term debt, net
|
13,392 | 602 | ||||||
Principal
payments on long-term debt
|
(303 | ) | (561 | ) | ||||
Cash
dividends paid
|
(2,133 | ) | (2,138 | ) | ||||
Stock
option transactions and other
|
5 | 1 | ||||||
Net
cash provided by financing activities
|
9,635 | 848 | ||||||
Effect
of exchange-rate changes on cash and cash equivalents
|
(23 | ) | (28 | ) | ||||
Net
decrease in cash and cash equivalents
|
(875 | ) | (1,393 | ) | ||||
Cash
and cash equivalents at beginning of period
|
2,122 | 3,406 | ||||||
Cash
and cash equivalents at end of period
|
$ | 1,247 | $ | 2,013 | ||||
Supplemental Cash Flow
Information:
|
||||||||
Cash paid during the period
for:
|
||||||||
Income taxes
|
$ | 454 | $ | 640 | ||||
Interest
|
84 | 166 |
(millions
of dollars)
|
First
Quarter
|
||||||||
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||||
Revenues
– Revenues(a)
|
$ | 132 | $ | 100 | |||||
Revenues
– Alliance revenues (b)
|
582 | 488 | |||||||
Total
Revenues
|
714 | 588 | |||||||
Cost
of sales (c)
|
(56 | ) | (31 | ) | |||||
Selling,
informational and administrative expenses
|
(17 | ) | (7 | ) | |||||
Research
and development expenses(d)
|
(194 | ) | (50 | ) |
(a)
|
Represents
sales to our partners of products manufactured by
us.
|
(b)
|
Substantially
all related to amounts earned from our partners under co-promotion
agreements.
|
(c)
|
Primarily
related to royalties earned by our partners and cost of sales associated
with inventory purchased from our
partners.
|
(d)
|
Primarily
related to net reimbursements earned by our partners except that the first
quarter of 2009 also includes a $150 million milestone payment to one of
our partners.
|
First
Quarter
|
|||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
|||||||
Implementation
costs(a)
|
$ | 174 | $ | 357 | |||||
Restructuring
charges(b)
|
157 | 178 | |||||||
Total
costs related to our cost-reduction initiatives
|
$ | 331 | $ | 535 |
(a)
|
For
the first quarter of 2009, included in Cost of sales ($76
million), Selling,
informational and administrative expenses ($46 million), Research and development
expenses ($41 million), and Other (income)/deductions –
net ($11 million). For the first quarter of 2008, included in Cost of sales ($138 million), Selling, informational and
administrative expenses ($75 million), Research and development
expenses ($146 million), and Other
(income)/deductions-net ($2 million income).
|
(b)
|
Included
in Restructuring charges
and acquisition-related
costs.
|
(millions
of dollars)
|
Costs
Incurred
Through
Mar.
29,
2009
|
Activity
Through
Mar.
29,
2009(a)
|
Accrual
as
of
Mar.
29,
2009(b)
|
||||||||||
Employee
termination costs
|
$ | 5,285 | $ | 3,500 | $ | 1,785 | |||||||
Asset
impairments
|
1,311 | 1,311 | – | ||||||||||
Other
|
444 | 412 | 32 | ||||||||||
Total
restructuring charges
|
$ | 7,040 | $ | 5,223 | $ | 1,817 |
(a)
|
Includes
adjustments for foreign currency translation.
|
(b)
|
Included in Other current liabilities
($1.240 billion) and Other noncurrent liabilities
($577
million).
|
First
Quarter
|
|||||
(millions
of dollars)
|
Mar. 29,
2009
|
||||
Transaction
costs (a)
|
$ | 369 | |||
Pre-integration
costs and other(b)
|
28 | ||||
Total
acquisition-related costs(c)
|
$ | 397 |
(a)
|
Transaction
costs include banking, legal, accounting and other costs directly related
to our pending acquisition of Wyeth. Substantially all of the costs
incurred to date are fees related to our $22.5 billion bridge term loan
credit agreement entered into with financial institutions on March 12,
2009 (see Note 8C.
Financial Instruments: Long-Term Debt) to partially fund our pending
acquisition of Wyeth. Upon our issuance of $13.5 billion of senior
unsecured notes on March 24, 2009, the commitment under the bridge term
loan credit agreement was reduced by an amount equal to the net proceeds
we received from such issuance, to a current balance of $9.1 billion, and,
accordingly, we expensed the portion of the bridge term loan credit
agreement fees associated with the $13.5 billion
reduction.
|
(b)
|
Pre-integration
costs represent external, incremental costs directly related to our
pending acquisition of Wyeth and include costs associated with preparing
for systems and other integration
activities.
|
(c)
|
Included
in Restructuring charges
and acquisition-related
costs.
|
First
Quarter
|
|||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
|||||||
Net
income before allocation to noncontrolling interests
|
$ | 2,730 | $ | 2,790 | |||||
Other
comprehensive loss:
|
|||||||||
Currency translation adjustment
and other
|
$ | (384 | ) | $ | (575 | ) | |||
Net unrealized gains/(losses) on
derivative financial instruments
|
(23 | ) | 1 | ||||||
Net unrealized gains/(losses) on
available-for-sale securities
|
145 | (14 | ) | ||||||
Benefit plan
adjustments
|
159 | 84 | |||||||
Total other comprehensive
loss
|
(103 | ) | (504 | ) | |||||
Total
comprehensive income before allocation to noncontrolling
interests
|
2,627 | 2,286 | |||||||
Less: Comprehensive income
attributable to noncontrolling interests
|
2 | 8 | |||||||
Comprehensive
income attributable to Pfizer Inc.
|
$ | 2,625 | $ | 2,278 |
(millions
of dollars)
|
Maturity
Date
|
2009
|
||||||
Senior
unsecured notes:
|
||||||||
Floating rate notes at the
three-month London Interbank
Offering
Rate (LIBOR), plus 1.95%
|
March
2011
|
$ | 1,250 | |||||
4.45%(a)
|
March
2012
|
3,500 | ||||||
5.35%(a)
|
March
2015
|
3,000 | ||||||
6.20%(a)
|
March
2019
|
3,250 | ||||||
7.20%(a)
|
March
2039
|
2,500 | ||||||
Total
long-term debt issued in connection with the pending acquisition of
Wyeth
|
$ | 13,500 |
(a)
|
The
fixed-rate debt is callable at any time at the greater of 100% of the
principal amount or the sum of the present
values of principal and interest discounted at the U.S. Treasury rate,
plus
0.50%.
|
·
|
We
defer on the balance sheet the effective portion of the gains or losses on
foreign currency forward-exchange contracts and foreign currency swaps
that are designated as cash flow hedges and reclassify those amounts, as
appropriate, into earnings in the same
period or periods during which the hedged transaction affects
earnings.
|
·
|
We
recognize the gains and losses on forward-exchange contracts and foreign
currency swaps that are used to offset the same foreign currency assets or
liabilities immediately into earnings along with the earnings impact of
the items they generally offset. These contracts essentially take the
opposite currency position of that reflected in the month-end balance
sheet to counterbalance the effect of any currency
movement.
|
·
|
We
recognize the gains and losses impact on foreign currency swaps designated
as hedges of our net investments in earnings in three ways:
over time–for the periodic net swap payments; immediately–to the extent of
any change in the difference between the foreign exchange spot rate and
forward rate; and upon sale or substantial liquidation of our net
investments–to the extent of change in the foreign exchange spot
rates.
|
·
|
We
recognize the gains and losses on interest rate swaps that are designated
as fair value hedges in earnings upon the
recognition of the change in fair value of the hedged risk. We recognize
the offsetting earnings impact of fixed-rate debt attributable to the
hedged risk also in earnings.
|
March
29, 2009
|
||||||||||
Assets
|
Liabilities
|
|||||||||
(millions
of dollars)
|
Balance
Sheet
Location(a)
|
Fair
Value(b)
|
Balance
Sheet
Location(a)
|
Fair
Value (b)
|
||||||
Derivative
financial instruments designated as hedging instruments:
|
||||||||||
Interest
rate swaps
|
OCA
|
$ | 1 |
OCL
|
$ | – | ||||
Interest
rate swaps
|
ONCA
|
314 |
ONCL
|
9 | ||||||
Foreign
currency swaps
|
OCA
|
17 |
OCL
|
6 | ||||||
Foreign
currency swaps
|
ONCA
|
143 |
ONCL
|
30 | ||||||
Foreign
currency forward-exchange contracts
|
OCA
|
276 |
OCL
|
266 | ||||||
Total
derivative financial instruments designated as hedging
instruments:
|
751 | 311 | ||||||||
Derivative
financial instruments not designated as hedging
instruments:
|
||||||||||
Foreign
currency swaps
|
ONCA
|
– |
ONCL
|
139 | ||||||
Foreign
currency forward-exchange contracts
|
OCA
|
233 |
OCL
|
650 | ||||||
Total
derivative financial instruments not designated as hedging
instruments
|
233 | 789 | ||||||||
Total
derivative financial instruments
|
$ | 984 | $ | 1,100 | ||||||
Nonderivative
financial instruments designated as hedging instruments:
|
||||||||||
Foreign
currency short-term borrowings
|
STB
|
$ | 1,273 | |||||||
Foreign
currency long-term debt
|
LTD
|
1,927 | ||||||||
Total
nonderivative financial instruments designated as hedging
instruments
|
$ | 3,200 |
(a)
|
The
primary consolidated balance sheet caption indicates the financial
statement classification of the amount associated with the financial
instrument used to hedge or offset risk. The abbreviations used are
defined as follows: OCA = Taxes and other current
assets; ONCA = Other assets, deferred taxes
and deferred charges; OCL = Other current
liabilities; ONCL = Other noncurrent
liabilities; STB = Short-term
borrowings; and LTD = Long-term
debt.
|
(b)
|
See
Note 8E. Financial
Instruments: Fair Value for a description of the valuation
techniques used to determine fair
values.
|
First
Quarter 2009
|
||||||||||||
(millions
of dollars)
|
Amount
of
Gains/(Losses)
Recognized in
Earnings(b)
|
Amount
of
Gains/(Losses)
Recognized in
OCI
(Effective
Portion)(a)
(c)
|
Amount
of
Gains/(Losses)
Reclassified from
OCI
into Earnings
(Effective
Portion)(a)
(b)
|
|||||||||
Derivative
financial instruments in fair value hedge relationships:
|
||||||||||||
Interest rate
swaps
|
$ | (284 | ) | |||||||||
Foreign currency
swaps
|
(1 | ) | ||||||||||
Total
derivative financial instruments in fair value hedge
relationships
|
$ | (285 | ) | |||||||||
Derivative
financial instruments in cash flow
hedge
relationships:
|
||||||||||||
U.S. Treasury interest rate
locks
|
$ | (11 | ) | $ | (15 | ) | $ | – | ||||
Foreign currency
swaps
|
– | (19 | ) | |||||||||
Foreign currency forward-exchange
contracts
|
– | 2 | 10 | |||||||||
Total
derivative financial instruments in cash flow hedge
relationships
|
$ | (11 | ) | $ | (32 | ) | $ | 10 | ||||
Derivative
financial instruments in net investment hedge
relationships:
|
||||||||||||
Foreign currency
swaps
|
$ | (2 | ) | $ | 53 | |||||||
Total
derivative financial instruments in net investment hedge
relationships
|
$ | (2 | ) | $ | 53 | |||||||
Derivative
financial instruments not designated as hedge instruments:
|
||||||||||||
Foreign currency
swaps
|
$ | (5 | ) | |||||||||
Foreign currency forward-exchange
contracts
|
(255 | ) | ||||||||||
Total
derivative financial instruments not designated as hedge
instruments
|
$ | (260 | ) | |||||||||
Nonderivative
financial instruments designated as hedging instruments:
|
||||||||||||
Foreign
currency short-term borrowings
|
$ | – | $ | 110 | ||||||||
Foreign
currency long-term debt
|
– | 158 | ||||||||||
Total
nonderivative financial instruments designated as hedging
instruments
|
$ | – | $ | 268 |
(a)
|
OCI
= Other Comprehensive
income/(expense).
|
(b)
|
Included
in Other
income/deductions, net.
|
(c)
|
For
derivative financial instruments in cash flow hedge relationships,
included in OCI –
Derivative Financial Instruments. For derivative financial
instruments in net investment hedge relationships and foreign currency
debt designated as hedging instruments, included in OCI – Currency translation
adjustment.
|
(millions
of dollars)
|
As
of
Mar.
29,
2009
|
As
of
Dec.
31,
2008
|
|||||||
Financial
assets carried at fair value(a):
|
|||||||||
Trading
securities(b)
|
$ | 164 | $ | 190 | |||||
Available-for-sale
debt securities(c)
|
40,257 | 30,061 | |||||||
Available-for-sale
money market funds(d)
|
4,031 | 398 | |||||||
Available-for-sale
equity securities, excluding money market funds(e)
|
148 | 319 | |||||||
Derivative
financial instruments(f)
|
984 | 1,259 | |||||||
Total
|
$ | 45,584 | $ | 32,227 | |||||
Other
financial assets:
|
|||||||||
Held-to-maturity
debt securities carried at amortized cost(g)
|
$ | 840 | $ | 2,349 | |||||
Short-term
loans carried at cost
|
793 | 824 | |||||||
Long-term
loans carried at cost(b)
|
1,404 | 1,568 | |||||||
Non-traded
equity securities carried at cost(b)
|
181 | 182 | |||||||
Total
|
$ | 3,218 | $ | 4,923 | |||||
Financial
liabilities carried at fair value (a):
|
|||||||||
Derivative
financial instruments(h)
|
$ | 1,100 | $ | 1,243 | |||||
Total
|
$ | 1,100 | $ | 1,243 | |||||
Financial
liabilities carried at historical proceeds:
|
|||||||||
Short-term
borrowings
|
$ | 7,613 | $ | 9,320 | |||||
Long-term
debt, including adjustments for fair value hedges of interest rate
risk
|
21,064 | 7,963 | |||||||
Total
|
$ | 28,677 | $ | 17,283 |
(a)
|
Fair
values are determined based on valuation techniques categorized as
follows: Level 1 means the use of quoted prices for identical instruments
in active markets; Level 2 means the use of quoted prices for similar
instruments in active markets or quoted prices for identical or similar
instruments in markets that are not active or are directly or indirectly
observable; Level 3 means the use of unobservable inputs. Virtually all of
our financial assets and liabilities carried at fair value use Level 2
inputs in the calculation of fair value, except that included in
available-for-sale equity securities, excluding money market funds, are
$79 million as of March 29, 2009 and $87 million as of December 31, 2008
of investments that use Level 1 inputs in the calculation of fair value.
None of our financial instruments are valued based on Level 3 inputs at
March 29, 2009 or December 31,
2008.
|
(b)
|
Included
in Long-term investments
and loans.
|
(c)
|
As
of March 29, 2009, included in Short-term investments
($28.633 billion) and Long-term investments and
loans ($11.624 billion). As of December
31, 2008, included in Short-term investments
($20.856
billion) and Long-term investments and
loans ($9.205 billion).
|
(d)
|
Included
in Short-term
investments.
|
(e)
|
As
of March 29, 2009, included in Long-term investments and
loans and includes gross unrealized gains ($8 million) and gross
unrealized losses ($36 million). As of December 31, 2008, included in
Long-term investments
and loans and includes gross unrealized gains ($17 million) and
gross unrealized losses ($39
million).
|
(f)
|
As
of March 29, 2009, included in Taxes and other current
assets ($527 million) and Other assets, deferred taxes
and deferred charges ($457 million). As of December 31, 2008,
included in Taxes and
other current assets ($404 million) and Other assets, deferred taxes
and deferred charges ($855
million).
|
(g)
|
As
of March 29, 2009, included in Cash and cash
equivalents ($684 million), Short-term investments
($141 million) and Long-term investments and
loans ($15 million). As of December 31, 2008, included in Cash and cash equivalents
($1.980
billion), Short-term
investments ($355 million) and Long-term investments and
loans ($14 million).
|
(h)
|
As
of March 29, 2009, included in Other current
liabilities ($922 million) and Other noncurrent liabilities ($178
million). As of December 31, 2008, included in Other current
liabilities ($1.1 billion) and Other noncurrent liabilities
($124
million).
|
·
|
maintain
a no more than 2.75:1 ratio of consolidated debt to “Earnings Before
Interest, Taxes, Depreciation and Amortization” (EBITDA), as defined.
EBITDA, as defined, permits add-backs of certain other charges such as
acquisition-related costs, unusual costs or certain non-cash
charges.
|
·
|
reduce
the bridge credit agreement commitment or repay any outstanding
indebtedness under the bridge credit agreement as required in an amount
equal to the net proceeds of certain transactions not in the ordinary
course of business, such as specified asset sales or sales-leaseback
transactions, property loss events, or certain equity or debt
issuances;
|
·
|
not
declare or pay dividends on our common stock in excess of $0.32 per share
per quarter;
|
·
|
not
incur certain types of debt;
|
·
|
not
purchase or redeem our common stock in excess of $250 million dollars in
the aggregate; and
|
·
|
not
purchase U.S. businesses for cash consideration in excess of $500 million
in the aggregate or international businesses for cash consideration in
excess of $2.5 billion in the
aggregate.
|
·
|
the
absence of material adverse change in the business of Pfizer or Wyeth;
and
|
·
|
Pfizer
must maintain an unsecured long-term obligations rating of at least “A2”
(with stable or better outlook) and a commercial paper credit rating of at
least “P-1” from Moody’s Investors Service, and maintain a long-term
issuer credit rating of at least “A” (with stable or better outlook) and a
short-term issuer credit rating of at least “A-1” from Standard &
Poor’s.
|
(millions
of dollars)
|
Mar.
29,
2009
|
Dec.
31,
2008
|
||||||
Finished
goods
|
$ | 2,151 | $ | 2,024 | ||||
Work-in-process
|
1,483 | 1,527 | ||||||
Raw
materials and supplies
|
824 | 830 | ||||||
Total
inventories(a)
|
$ | 4,458 | $ | 4,381 |
(a)
|
Certain
amounts of inventories are in excess of one year’s supply. There are no
recoverability issues associated with these quantities and the amounts are
not significant.
|
(millions
of dollars)
|
Pharmaceutical
|
Animal
Health
|
Other
|
Total
|
||||||||||||
Balance,
December 31, 2008
|
$ | 21,317 | $ | 129 | $ | 18 | $ | 21,464 | ||||||||
Additions
|
– | – | – | – | ||||||||||||
Other(a)
|
22 | (4 | ) | – | 18 | |||||||||||
Balance,
March 29, 2009
|
$ | 21,339 | $ | 125 | $ | 18 | $ | 21,482 |
(a)
|
Primarily
related to the impact of foreign exchange, except that Pharmaceutical also
includes a reclassification of about $150 million to Assets held for
sale.
|
As
of Mar. 29, 2009
|
As
of Dec. 31, 2008
|
|||||||||||||||||||||||
(millions
of dollars)
|
Gross
Carrying
Amount
|
Accumulated
Amortization
|
Identifiable
Intangible
Assets,
less Accumulated Amortization
|
Gross
Carrying
Amount
|
Accumulated
Amortization
|
Identifiable
Intangible
Assets,
less
Accumulated
Amortization
|
||||||||||||||||||
Finite-lived
intangible assets:
|
||||||||||||||||||||||||
Developed
technology rights
|
$ | 31,101 | $ | (18,059 | ) | $ | 13,042 | $ | 31,484 | $ | (17,673 | ) | $ | 13,811 | ||||||||||
Brands
|
1,016 | (496 | ) | 520 | 1,016 | (487 | ) | 529 | ||||||||||||||||
License
agreements
|
246 | (84 | ) | 162 | 246 | (78 | ) | 168 | ||||||||||||||||
Trademarks
|
119 | (79 | ) | 40 | 118 | (78 | ) | 40 | ||||||||||||||||
Other(a)
|
524 | (296 | ) | 228 | 531 | (291 | ) | 240 | ||||||||||||||||
Total
amortized finite-lived
|
||||||||||||||||||||||||
intangible assets
|
33,006 | (19,014 | ) | 13,992 | 33,395 | (18,607 | ) | 14,788 | ||||||||||||||||
Indefinite-lived
intangible assets:
|
||||||||||||||||||||||||
Brands
|
2,860 | – | 2,860 | 2,860 | – | 2,860 | ||||||||||||||||||
Trademarks
|
68 | – | 68 | 70 | – | 70 | ||||||||||||||||||
Other
|
3 | – | 3 | 3 | – | 3 | ||||||||||||||||||
Total
indefinite-lived
|
||||||||||||||||||||||||
intangible assets
|
2,931 | – | 2,931 | 2,933 | – | 2,933 | ||||||||||||||||||
Total
identifiable intangible assets
|
$ | 35,937 | $ | (19,014 | ) | $ | 16,923 | (b) | $ | 36,328 | $ | (18,607 | ) | $ | 17,721 |
(a)
|
Includes
patents, non-compete agreements, customer contracts and other intangible
assets.
|
(b)
|
Decrease
from December 31, 2008 as compared to the prior period is primarily
related to amortization and the impact of foreign
exchange.
|
Pension
Plans
|
||||||||||||||||||||||||||||||||
U.S.
Qualified
|
U.S.
Supplemental
(Non-Qualified)
|
International
|
Postretirement
Plans
|
|||||||||||||||||||||||||||||
(millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
2009
|
2008
|
2009
|
2008
|
||||||||||||||||||||||||
Service
cost
|
$ | 59 | $ | 61 | $ | 5 | $ | 6 | $ | 45 | $ | 63 | $ | 8 | $ | 9 | ||||||||||||||||
Interest
cost
|
119 | 116 | 13 | 12 | 78 | 99 | 30 | 34 | ||||||||||||||||||||||||
Expected
return on plan assets
|
(118 | ) | (163 | ) | – | – | (86 | ) | (111 | ) | (6 | ) | (9 | ) | ||||||||||||||||||
Amortization
of:
|
||||||||||||||||||||||||||||||||
Actuarial losses
|
57 | 8 | 8 | 9 | 6 | 11 | 4 | 6 | ||||||||||||||||||||||||
Prior service
costs/(credits)
|
1 | 1 | (1 | ) | (1 | ) | (1 | ) | – | (1 | ) | – | ||||||||||||||||||||
Curtailments
and settlements – net
|
24 | 3 | 7 | 112 | 2 | (2 | ) | 5 | 3 | |||||||||||||||||||||||
Special
termination benefits
|
13 | 7 | – | – | 1 | 7 | 12 | 4 | ||||||||||||||||||||||||
Net
periodic benefit costs
|
$ | 155 | $ | 33 | $ | 32 | $ | 138 | $ | 45 | $ | 67 | $ | 52 | $ | 47 |
First
Quarter
|
||||||||
(millions)
|
|
Mar.
29,
2009
|
Mar.
30,
2008
|
|||||
EPS
Numerator - Basic:
|
||||||||
Income from continuing operations
attributable to Pfizer Inc.
|
$ | 2,728 | $ | 2,788 | ||||
Less: Preferred stock dividends -
net of tax
|
– | – | ||||||
Income from continuing operations
attributable to Pfizer Inc.
common
shareholders
|
2,728 | 2,788 | ||||||
Discontinued operations - net of
tax
|
1 | (4 | ) | |||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 2,729 | $ | 2,784 | ||||
EPS
Denominator - Basic:
|
||||||||
Weighted-average number of common
shares outstanding
|
6,723 | 6,739 | ||||||
EPS
Numerator - Diluted:
|
||||||||
Income from continuing operations
attributable to Pfizer Inc.
|
$ | 2,728 | $ | 2,788 | ||||
Less: ESOP contribution - net of
tax
|
– | – | ||||||
Income from continuing operations
attributable to Pfizer Inc.
common
shareholders
|
2,728 | 2,788 | ||||||
Discontinued operations - net of
tax
|
1 | (4 | ) | |||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 2,729 | $ | 2,784 | ||||
EPS
Denominator - Diluted:
|
||||||||
Weighted-average number of common
shares outstanding
|
6,723 | 6,739 | ||||||
Common share equivalents: stock
options, restricted stock units,
stock
issuable under other employee compensation plans and
convertible
preferred stock
|
30 | 23 | ||||||
Weighted-average number of common
shares outstanding and
common
share equivalents
|
6,753 | 6,762 | ||||||
Stock options that had exercise
prices greater than the average
market
price of our common stock issuable under employee
compensation
plans (a)
|
475 | 551 |
(a)
|
These
common stock equivalents were outstanding during the first quarters of
2009 and 2008, but were not included in the computation of diluted EPS for
those periods because their inclusion would have had an anti-dilutive
effect.
|
·
|
The
Pharmaceutical segment includes products that prevent and treat
cardiovascular and metabolic diseases, central nervous system disorders,
arthritis and pain, infectious and respiratory diseases, urogenital
conditions, cancer, eye diseases and endocrine disorders, among
others.
|
·
|
The
Animal Health segment includes products that prevent and treat diseases in
livestock and companion animals.
|
First
Quarter
|
||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||
Revenues
|
||||||||
Pharmaceutical
|
$ | 10,102 | $ | 10,904 | ||||
Animal Health
|
537 | 619 | ||||||
Corporate/Other(a)
|
228 | 325 | ||||||
Total
revenues
|
$ | 10,867 | $ | 11,848 | ||||
Segment
profit/(loss)(b)
|
||||||||
Pharmaceutical
|
$ | 5,407 | $ | 5,594 | ||||
Animal Health
|
132 | 145 | ||||||
Corporate/Other(a)
|
(1,736 | )(c) | (2,182 | )(d) | ||||
Total
profit/(loss)
|
$ | 3,803 | $ | 3,557 |
(a)
|
Corporate/Other
includes our gelatin capsules business, our contract manufacturing
business and a bulk pharmaceutical chemicals business, and transition
activity associated with our former Consumer Healthcare business (sold in
December 2006). Corporate/Other under
Segment profit/(loss) also
includes interest income/(expense), corporate expenses (e.g., corporate
administration costs), other income/(expense) (e.g., realized gains and
losses attributable to our investments in debt and equity securities),
certain performance-based and all share-based compensation expenses,
significant impacts of purchase accounting for acquisitions,
acquisition-related costs, intangible asset impairments and costs related
to our cost-reduction initiatives. This methodology is utilized by
management to evaluate our
businesses.
|
(b)
|
Segment profit/(loss)
equals Income
from continuing operations before provision for taxes on
income.
|
(c)
|
For
the first quarter of 2009, Corporate/Other
includes: (i) significant impacts of purchase accounting for
acquisitions of $546 million, including intangible asset amortization and
other charges, primarily related to our acquisition of Pharmacia in 2003;
(ii) acquisition-related costs of $397 million, primarily related to our
pending acquisition of Wyeth; (iii) restructuring charges and
implementation costs associated with our cost-reduction initiatives of
$331 million; and (iv) all share-based compensation
expense.
|
(d)
|
For
the first quarter of 2008, Corporate/Other
includes: (i) significant impacts of purchase accounting for acquisitions
of $1.2 billion, including acquired in-process research and development
intangible asset amortization and other charges; (ii) restructuring
charges and implementation costs associated with our cost-reduction
initiatives of $534 million; (iii) all share-based compensation expense;
and (iv) acquisition-related costs of $1
million.
|
First
Quarter
|
||||||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
%
Change
|
|||||||||
PHARMACEUTICAL:
|
||||||||||||
Cardiovascular
and metabolic diseases
|
$ | 3,953 | $ | 4,494 | (12 | ) | ||||||
Central
nervous system disorders
|
1,431 | 1,386 | 3 | |||||||||
Arthritis
and pain
|
688 | 755 | (9 | ) | ||||||||
Infectious
and respiratory diseases
|
933 | 931 | – | |||||||||
Urology
|
767 | 784 | (2 | ) | ||||||||
Oncology
|
552 | 637 | (13 | ) | ||||||||
Ophthalmology
|
413 | 413 | – | |||||||||
Endocrine
disorders
|
252 | 258 | (2 | ) | ||||||||
All
other
|
531 | 758 | (30 | ) | ||||||||
Alliance
revenues
|
582 | 488 | 19 | |||||||||
Total
Pharmaceutical
|
10,102 | 10,904 | (7 | ) | ||||||||
ANIMAL
HEALTH
|
537 | 619 | (13 | ) | ||||||||
OTHER
|
228 | 325 | (30 | ) | ||||||||
Total
revenues
|
$ | 10,867 | $ | 11,848 | (8 | ) |
First
Quarter
|
||||||||||||
(millions
of dollars)
|
2009
|
2008
|
%
Change
|
|||||||||
Revenues
|
||||||||||||
United States(a)
|
$ | 4,969 | $ | 5,511 | (10 | ) | ||||||
Europe(b)
|
3,005 | 3,413 | (12 | ) | ||||||||
Japan/Asia(c)
|
1,738 | 1,573 | 11 | |||||||||
Canada/Latin America/AFME(d)
|
1,155 | 1,351 | (14 | ) | ||||||||
Total
Revenues
|
$ | 10,867 | $ | 11,848 | (8 | ) |
(a)
|
Includes
operations in Puerto Rico.
|
(b) | Includes France, Italy, Spain, Germany, the U.K., Ireland, Northern Europe and Central-South Europe. |
(c) | Includes Japan, Australia, Korea, China, Taiwan, Thailand, Singapore and India. |
(d) | Includes Canada, South America, Central America, Mexico, Africa and the Middle East. |
·
|
Overview of Our Performance
and Operating Environment. This section, beginning on page 24,
provides information about the following: our business; our performance
during the first quarter of 2009; our operating environment; our strategic
initiatives; and our cost-reduction
initiatives.
|
·
|
Revenues. This section,
beginning on page 29, provides an analysis of our products and revenues
for the first quarters of 2009 and 2008, as well as an overview of
important product developments.
|
·
|
Costs and Expenses.
This section, beginning on page 38, provides a discussion about our costs
and expenses.
|
·
|
Provision for Taxes on
Income. This section, on page 40, provides a discussion of items
impacting our tax provision for the periods
presented.
|
·
|
Adjusted Income. This
section, beginning on page 40, provides a discussion of an alternative
view of performance used by
management.
|
·
|
Financial Condition, Liquidity
and Capital Resources. This section, beginning on page 44, provides
an analysis of our balance sheets as of March 29, 2009 and December 31,
2008 and cash flows for the first quarters of 2009 and 2008, as well as a
discussion of our outstanding debt and commitments that existed as of
March 29, 2009, and December 31, 2008. Included in the discussion of
outstanding debt is a discussion of the amount of financial capacity
available to help fund Pfizer’s future
activities.
|
·
|
Outlook. This section,
beginning on page 48, provides a discussion of our expectations for
full-year 2009.
|
·
|
Forward-Looking Information
and Factors That May Affect Future Results. This section, beginning
on page 49, provides a description of the risks and uncertainties that
could cause actual results to differ materially from those discussed in
forward-looking
statements set forth in this MD&A relating to our financial results,
operations and business plans and prospects. Such forward-looking
statements are based on management’s current expectations about future
events, which are inherently susceptible to uncertainty and changes in
circumstances. Also included in this section is a discussion of Legal
Proceedings and Contingencies.
|
First
Quarter
|
||||||||||||
(millions
of dollars, except per common share data)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
%
Change
|
|||||||||
|
||||||||||||
Revenues
|
$ | 10,867 | $ | 11,848 | (8 | ) | ||||||
Cost
of sales
|
1,408 | 1,986 | (29 | ) | ||||||||
% of revenues
|
13.0 | % | 16.8 | % | ||||||||
Selling,
informational and administrative expenses
|
2,876 | 3,492 | (18 | ) | ||||||||
% of revenues
|
26.5 | % | 29.5 | % | ||||||||
Research
and development expenses
|
1,705 | 1,791 | (5 | ) | ||||||||
% of revenues
|
15.7 | % | 15.1 | % | ||||||||
Amortization
of intangible assets
|
578 | 779 | (26 | ) | ||||||||
% of revenues
|
5.3 | % | 6.6 | % | ||||||||
Acquisition-related
in-process research and development charges
|
– | 398 | (100 | ) | ||||||||
% of revenues
|
– | % | 3.4 | % | ||||||||
Restructuring
charges and acquisition-related costs
|
554 | 178 | 212 | |||||||||
% of revenues
|
5.1 | % | 1.5 | % | ||||||||
Other
(income)/deductions – net
|
(57 | ) | (333 | ) | (82 | ) | ||||||
Income
from continuing operations before provision for taxes on
income
|
3,803 | 3,557 | 7 | |||||||||
% of
revenues
|
35.0 | % | 30.0 | % | ||||||||
Provision
for taxes on income
|
1,074 | 763 | 41 | |||||||||
Effective
tax rate
|
28.2 | % | 21.5 | % | ||||||||
Income
from continuing operations
|
2,729 | 2,794 | (2 | ) | ||||||||
% of revenues
|
25.1 | % | 23.6 | % | ||||||||
Discontinued
operations – net of tax
|
1 | (4 | ) | * | ||||||||
Net
income before allocation to noncontrolling interests
|
2,730 | 2,790 | (2 | ) | ||||||||
% of revenues
|
25.1 | % | 23.5 | % | ||||||||
Less:
Net income attributable to noncontrolling interests
|
1 | 6 | (78 | ) | ||||||||
Net
income attributable to Pfizer Inc.
|
$ | 2,729 | $ | 2,784 | (2 | ) | ||||||
% of revenues
|
25.1 | % | 23.5 | % | ||||||||
Earnings
per common share - basic:
|
||||||||||||
Income from continuing operations
attributable to Pfizer Inc.
common
shareholders
|
$ | 0.41 | $ | 0.41 | – | |||||||
Discontinued operations - net of
tax
|
– | – | – | |||||||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 0.41 | $ | 0.41 | – | |||||||
Earnings
per common share - diluted:
|
||||||||||||
Income from continuing operations
attributable to Pfizer Inc.
common
shareholders
|
$ | 0.40 | $ | 0.41 | (2 | ) | ||||||
Discontinued operations - net of
tax
|
– | – | – | |||||||||
Net income attributable to Pfizer
Inc. common shareholders
|
$ | 0.40 | $ | 0.41 | (2 | ) | ||||||
Cash
dividends paid per common share
|
$ | 0.32 | $ | 0.32 |
First
Quarter
|
||||||||
(millions
of dollars)
|
Increase/
(decrease)
09/08
|
%
Change
09/08
|
||||||
Lipitor(a)
|
$ | (416 | ) | (13 | ) | |||
Zyrtec/Zyrtec
D(b)
|
(117 | ) | (100 | ) | ||||
Chantix/Champix(c)
|
(100 | ) | (36 | ) | ||||
Camptosar(b)
|
(83 | ) | (43 | ) | ||||
Celebrex
|
(47 | ) | (8 | ) | ||||
Norvasc(d)
|
(32 | ) | (6 | ) | ||||
Detrol/Detrol
LA
|
(24 | ) | (8 | ) | ||||
Geodon/Zeldox
|
(11 | ) | (5 | ) | ||||
Genotropin
|
(9 | ) | (4 | ) | ||||
Viagra
|
(6 | ) | (1 | ) | ||||
Xalatan/Xalacom
|
2 | – | ||||||
Vfend
|
8 | 5 | ||||||
Sutent
|
12 | 7 | ||||||
Zyvox
|
24 | 9 | ||||||
Lyrica
|
102 | 17 | ||||||
Alliance
revenues
|
94 | 19 |
(a) | Lipitor has been impacted by competitive pressures and other factors. |
(b)
|
Zyrtec/Zyrtec
D lost U.S. exclusivity in late January 2008, at which time we ceased
selling this product. Camptosar lost U.S. exclusivity in February
2008.
|
(c)
|
Chantix/Champix
has been negatively impacted by the changes to its label in
2008.
|
(d)
|
Norvasc
lost U.S. exclusivity in March
2007.
|
·
|
the
decrease in total revenues due to the unfavorable impact of foreign
exchange, among other factors;
|
·
|
the
decrease in other
income/deductions;
|
·
|
the
increase in the effective tax rate;
and
|
·
|
costs
incurred in connection with the pending Wyeth
acquisition;
|
·
|
savings
related to our cost-reduction initiatives;
and
|
·
|
the
elimination of acquisition-related
in-process research and development charges in 2009 compared
to $398 million
|
|
in
the first quarter of 2008.
|
·
|
In
the first quarter of 2009, we entered into a five-year agreement with
Bausch & Lomb to co-promote prescription pharmaceuticals in the U.S.
for the treatment of ophthalmic conditions. The agreement
covers prescription ophthalmic pharmaceuticals, including our Xalatan
product and Bausch & Lomb’s Alrex®, Lotemax® and Zylet® products, as
well as Bausch & Lomb’s investigational anti-infective eye drop,
besifloxacin ophthalmic suspension, 0.6%, which is currently under review
by the U.S. Food and Drug Administration
(FDA).
|
·
|
In
the first quarter of 2008, we acquired CovX, a privately held
biotherapeutics company specializing in preclinical oncology and metabolic
research and the developer of a biotherapeutics technology platform that
we expect will enhance our biologic portfolio. Also in the first quarter
of 2008, we acquired all the outstanding shares of Coley Pharmaceutical
Group, Inc. (Coley), a biopharmaceutical company specializing in vaccines
and drug candidates designed to fight cancers, allergy and asthma
disorders, and autoimmune diseases, for approximately $230 million. In
connection with these and two smaller acquisitions related to Animal
Health, we recorded approximately $398 million in Acquisition-related in-process
research and development
charges.
|
·
|
On
April 16, 2009, we announced that we entered into an agreement with
GlaxoSmithKline plc (GSK) to create a new company focused solely on
research, development and commercialization of HIV medicines. We and GSK
will contribute product and pipeline assets to the new company. The new
company will have a broad product portfolio of 11 marketed products,
including innovative leading therapies such as GSK’s Combivir and Kivexa products and our Selzentry/Celsentri
(maraviroc) product. The company will have a pipeline of six
innovative and targeted medicines, including four compounds in Phase 2
development. The new company will contract R&D and manufacturing
services directly from GSK and us and will also enter into a new research
alliance agreement with GSK and us. Under this new alliance, the new
company will invest in our and GSK’s programs for discovery research and
development into HIV medicines. The new company will have exclusive rights
of first negotiation in relation to any new HIV-related medicines
developed by either GSK or us. We will initially hold a 15% equity
interest in the new company, and GSK will hold an 85% equity interest. The
equity interests will be adjusted in the event that specified sales and
regulatory milestones are achieved. Our equity interest in the new company
could vary from 9% to 30.5%, and GSK’s equity interest in the new company
could vary from 69.5% to 91%, depending upon the milestones achieved with
respect to the original pipeline assets contributed by us and by GSK to
the new company. Each company may also be entitled to preferential
dividend payments to the extent that specific sales thresholds are met in
respect of the marketed products and pipeline assets originally
contributed. We will account for our share of the new company as an equity
method investment. The closing of
the transaction and commencement of the new company’s business is
conditional upon certain matters, including receiving certain regulatory
and tax clearances, and no material adverse change occurring in respect of
either GSK’s or our
HIV business prior to closing. We and GSK will conduct consultations with
works councils in accordance with applicable employment legislation. The
transaction is expected to close in the fourth quarter of
2009.
|
·
|
On
January 26, 2009, we announced that we entered into a definitive merger
agreement under which we will acquire Wyeth in a cash-and-stock
transaction valued on that date at $50.19 per share, or a total of $68
billion. The Boards of Directors of both Pfizer and Wyeth have approved
the transaction. Under the terms of the merger agreement, each outstanding
share of Wyeth common stock will be converted into the right to receive
$33 in cash and 0.985 of a share of Pfizer common stock, subject to
adjustment as set forth in the merger agreement. Each outstanding Wyeth
stock option, and each outstanding share of Wyeth restricted stock,
deferred stock unit award and restricted stock unit award, will be
exchanged for cash in accordance with the terms of the merger agreement.
In addition, the merger agreement provides that each share of Wyeth $2
convertible preferred stock will be exchanged for a newly created class of
Pfizer preferred stock having substantially the same rights as the Wyeth
$2 convertible preferred stock. However, on April 23, 2009, Wyeth
announced that it will affect a full redemption of its outstanding $2
convertible preferred stock effective on July 15, 2009. As a result, we
will not issue any preferred stock in connection with the
merger.
|
We expect the Wyeth transaction will close at the end of the third quarter or during the fourth quarter of 2009, subject to Wyeth shareholder approval, governmental and regulatory approvals, the satisfaction of the conditions related to the debt financing for the transaction, and other usual and customary closing conditions. We believe that the combination of Pfizer and Wyeth will create the world’s premier biopharmaceutical company and will meaningfully deliver on Pfizer’s strategic priorities in a single transaction. The combined entity will be one of the most diversified in the industry and will enable us to offer patients a uniquely broad and diversified portfolio of biopharmaceutical innovation through patient-centric units. | |
We expect to achieve annual cost savings of approximately $4 billion by the end of 2012 related solely to this transaction. We expect we will incur acquisition-related restructuring charges and integration costs associated with the expected cost savings, which we estimate could be in the range of approximately $6 billion to $8 billion, and which will be expensed as incurred. | |
We
expect to fund the acquisition through a combination of cash, stock,
short-term borrowings and long-term debt. (See Notes to Condensed
Consolidated Financial Statements - Note 8B. Financial
Instruments: Short-Term Borrowings, Note 8C. Financial Instruments: Long-Term
Debt and Note 8G. Financial
Instruments: Credit Covenants.)
|
|
The
merger agreement with Wyeth prohibits us from making acquisitions, except
for acquisitions for which cash consideration does not exceed $750 million
in the aggregate prior to the completion of the transaction without
Wyeth’s consent. In addition, the 364-day bridge term loan credit
agreement that we entered into on March 12, 2009 (bridge credit agreement)
in connection with the pending Wyeth acquisition prohibits us from
purchasing U.S. domestic businesses for cash consideration in excess of
$500 million in the aggregate or international businesses for cash
consideration in excess of $2.5 billion in the aggregate until the
commitment expires or is terminated and all loans under the agreement, if
any, have been paid. (For further discussion of the bridge credit
agreement, see the “Financial Condition, Liquidity and Capital Resources”
section of this MD&A and Notes to the Condensed Consolidated Financial
Statements – Note 8B.
Financial Instruments: Short-Term Borrowings and Note 8G. Financial
Instruments: Credit
Covenants).
|
·
|
Creating a More Agile and
Productive Organization—In January 2009, we announced that we plan
to reduce our global research staff. We expect these reductions, which are
part of the planned 10% total workforce reduction discussed above, will be
completed during 2009.
|
·
|
Supply Network Transformation - We are
transforming our global manufacturing network into a global strategic
supply network, consisting of our internal network of plants together with
strategic external manufacturers, and including purchasing, packaging and
distribution. As of the end of the first quarter of 2009, we have reduced
our internal network of plants from 93 in 2003 to 46, which includes the
acquisition of seven plants and the sites sold in 2006 as part of our
Consumer Healthcare business. We plan to reduce our internal network of
plants around the world to 41. We expect that the cumulative impact will
be a more focused, streamlined and competitive manufacturing operation,
with less than 50% of our former internal plants and more than 53% fewer
manufacturing employees, compared to 2003. As part of the transformation
to a global strategic supply network, we currently expect to increase
outsourced manufacturing from approximately 24% of our products, on a cost
basis, to approximately 30% over the next two
years.
|
·
|
Reorganization of our Field
Force - As part of Pfizer’s overall restructuring into smaller,
more focused business units, we have changed our global field force
operations to enable us to adapt to changing market dynamics and respond
to local customer needs more quickly and with more flexibility. This
process, which began in 2007, is generating savings from de-layering,
eliminating duplicative work, and utilizing our sales representatives more
efficiently through targeted deployment based on sophisticated
segmentation analyses, offset modestly by increased investment in certain
emerging markets. Between 2004 and the end of the first quarter of 2009,
we reduced our global field force by approximately 12%, with a substantial
portion of those reductions occurring since the beginning of
2007.
|
Three
Months Ended
|
%
Change in Revenues
|
|||||||||||||||||||||||||||||||||||
|
|
World-
|
|
Inter-
|
||||||||||||||||||||||||||||||||
Worldwide
|
U.S.
|
International
|
wide
|
U.S.
|
national
|
|||||||||||||||||||||||||||||||
(millions of |
Mar.
29,
|
Mar.
30,
|
Mar.
29,
|
Mar.
30,
|
Mar.
29,
|
Mar.
30,
|
|
|
|
|||||||||||||||||||||||||||
dollars)
|
2009
|
2008
|
2009
|
2008
|
2009
|
2008
|
09/08
|
09/08
|
09/08
|
|||||||||||||||||||||||||||
Pharmaceutical
|
$ | 10,102 | $ | 10,904 | $ | 4,709 | $ | 5,141 | $ | 5,393 | $ | 5,763 | (7 | ) | (8 | ) | (7 | ) | ||||||||||||||||||
Animal
Health
|
537 | 619 | 194 | 240 | 343 | 379 | (13 | ) | (19 | ) | (10 | ) | ||||||||||||||||||||||||
Other
|
228 | 325 | 66 | 130 | 162 | 195 | (30 | ) | (49 | ) | (17 | ) | ||||||||||||||||||||||||
Total
Revenues
|
$ | 10,867 | $ | 11,848 | $ | 4,969 | $ | 5,511 | $ | 5,898 | (a) | $ | 6,337 | (a) | (8 | ) | (10 | ) | (7 | ) |
(a)
|
Includes
revenues from Japan of $993 million (9.1% of total revenues) for the first
quarter of 2009, and $765 million (6.5% of total revenues) for the first
quarter of 2008.
|
First
Quarter
|
||||||||||||
(millions
of dollars)
|
2009
|
2008
|
%
Change
|
|||||||||
PHARMACEUTICAL:
|
||||||||||||
Primary
care
|
$ | 5,322 | $ | 5,788 | (8 | ) | ||||||
Specialty
care
|
1,463 | 1,362 | 7 | |||||||||
Oncology
|
350 | 421 | (17 | ) | ||||||||
Established
products
|
1,615 | 1,841 | (12 | ) | ||||||||
Emerging
markets
|
1,352 | 1,492 | (9 | ) | ||||||||
Total
Pharmaceutical
|
10,102 | 10,904 | (7 | ) | ||||||||
ANIMAL
HEALTH
|
537 | 619 | (13 | ) | ||||||||
OTHER
|
228 | 325 | (30 | ) | ||||||||
Total
revenues
|
$ | 10,867 | $ | 11,848 | (8 | ) |
·
|
the
strengthening of the U.S. dollar relative to other currencies, primarily
the euro, UK pound and Canadian dollar, which unfavorably impacted
Pharmaceutical revenues by $574 million, or 5%, in the first quarter of
2009;
|
·
|
an
aggregate decrease in revenues for Zyrtec/Zyrtec D and Camptosar of $200
million in the first quarter of 2009, due to the loss of U.S. exclusivity
and cessation of selling of Zyrtec/Zyrtec D in January 2008 and the loss
of U.S. exclusivity of Camptosar in February
2008;
|
·
|
a
decrease in worldwide revenues for Lipitor of $416 million in the first
quarter of 2009, primarily resulting from competitive pressures from
generics, among other factors; and
|
·
|
a
decrease in worldwide revenues for Chantix/Champix of $100 million in the
first quarter of 2009, primarily resulting from changes to the Chantix
label during 2008, among other
factors;
|
·
|
solid
operational performance from certain products, including Lyrica,
Xalatan/Xalacom, Zyvox, Sutent and
Vfend.
|
·
|
in
the U.S., Pharmaceutical revenues decreased 8% in the first quarter of
2009, compared to the same period of 2008, primarily due to lower sales of
Lipitor, the effect of the loss of exclusivity of Zyrtec/Zyrtec D and
Camptosar, and lower sales of Chantix, which was negatively impacted by
the changes to its label in 2008 and other factors, partially offset by
the solid performance from certain products, including Lyrica, Viagra,
Zyvox and Xalatan; and
|
·
|
in
our international markets, Pharmaceutical revenues decreased 7% in the
first quarter of 2009, compared to the same period of 2008, due to the
unfavorable impact of foreign exchange on international revenues of $574
million, or 10%, partially offset by operational growth, including higher
revenues from certain products, including Lyrica, Zyvox and
Sutent.
|
First Quarter
|
|||||||||
%
Change
|
|||||||||
(millions
of dollars)
|
Mar.
29,
|
From
|
|||||||
Product+
|
Primary
Indications
|
2009
|
2008
|
||||||
Cardiovascular
and
|
|||||||||
metabolic
diseases:
|
|||||||||
Lipitor
|
Reduction
of LDL cholesterol
|
$ | 2,721 | (13 | ) | ||||
Norvasc
|
Hypertension
|
481 | (6 | ) | |||||
Chantix/Champix
|
An
aid to smoking cessation
|
177 | (36 | ) | |||||
Caduet
|
Reduction
of LDL cholesterol and hypertension
|
134 | (9 | ) | |||||
Cardura
|
Hypertension/Benign
prostatic hyperplasia
|
107 | (11 | ) | |||||
Central
nervous
|
|||||||||
system
disorders:
|
|||||||||
Lyrica
|
Epilepsy,
post-herpetic neuralgia and diabetic
peripheral neuropathy,
fibromyalgia
|
684 | 17 | ||||||
Geodon/Zeldox
|
Schizophrenia
and acute manic or mixed
episodes
associated with bipolar disorder
|
230 | (5 | ) | |||||
Zoloft
|
Depression
and certain anxiety disorders
|
115 | (6 | ) | |||||
Aricept(a),(b)
|
Alzheimer’s
disease
|
95 | (9 | ) | |||||
Relpax
|
Migraine
headaches
|
79 | 2 | ||||||
Neurontin
|
Epilepsy
and post-herpetic neuralgia
|
78 | (12 | ) | |||||
Xanax/Xanax XR
|
Anxiety/Panic
disorders
|
75 | (13 | ) | |||||
Arthritis
and pain:
|
|||||||||
Celebrex
|
Arthritis
pain and inflammation, acute pain
|
564 | (8 | ) | |||||
Infectious
and
|
|||||||||
respiratory
diseases:
|
|||||||||
Zyvox
|
Bacterial
infections
|
283 | 9 | ||||||
Vfend
|
Fungal
infections
|
179 | 5 | ||||||
Zithromax/Zmax
|
Bacterial
infections
|
114 | (5 | ) | |||||
Diflucan
|
Fungal
infections
|
78 | (13 | ) | |||||
Selzentry/Celsentri
|
HIV
infection
|
18 | 189 | ||||||
Urology:
|
|||||||||
Viagra
|
Erectile
dysfunction
|
454 | (1 | ) | |||||
Detrol/Detrol LA
|
Overactive
bladder
|
289 | (8 | ) | |||||
Oncology:
|
|||||||||
Sutent
|
Advanced
and/or metastatic renal cell carcinoma
(mRCC) and refractory
gastrointestinalstromal tumors (GIST)
|
202 | 7 | ||||||
Aromasin
|
Breast
cancer
|
110 | 6 | ||||||
Camptosar
|
Metastatic
colorectal cancer
|
109 | (43 | ) | |||||
Ophthalmology:
|
|||||||||
Xalatan/Xalacom
|
Glaucoma
and ocular hypertension
|
407 | – | ||||||
Endocrine
disorders:
|
|||||||||
Genotropin
|
Replacement
of human growth hormone
|
197 | (4 | ) | |||||
All
other:
|
|||||||||
Zyrtec/Zyrtec D
|
Allergies
|
– | (100 | ) | |||||
Alliance
revenues:
|
|||||||||
Aricept(b),,
Macugen,
Exforge,
Olmetec,
Rebif and Spiriva
|
Alzheimer’s
disease (Aricept), neovascular (wet)
age-related
macular degeneration (Macugen),
hypertension
(Exforge and Olmetec), multiple
sclerosis
(Rebif) and chronic obstructive
pulmonary
disease (Spiriva)
|
582 | 19 |
+
|
Revenues
are presented by therapeutic area.
|
Certain
amounts and percentages may reflect rounding
adjustments.
|
|
(a)
|
Represents
direct sales under license agreement with Eisai Co.,
Ltd.
|
(b)
|
See the discussion under “Aricept Strategic Alliance and Development Agreement” in Part II – Other Information; Item 1. Legal Proceedings. |
·
|
Lipitor, for the
treatment of elevated LDL-cholesterol levels in the blood, is the most
widely used prescription treatment for lowering cholesterol and the
best-selling pharmaceutical product of any kind in the world. Lipitor
recorded worldwide revenues of $2.7 billion in the first quarter of 2009,
a decrease of 13% compared to the same period in 2008. These results
reflect the negative impact of foreign exchange, which decreased revenues
by $186 million, or 6%. In the U.S., revenues of $1.5 billion in the first
quarter of 2009 declined 17%, compared with the same period in 2008.
Internationally, Lipitor revenues in the first quarter of 2009 decreased
9%, compared to the same period in 2008, with 13% due to the unfavorable
impact of foreign exchange.
|
·
|
the
unfavorable impact of foreign
exchange;
|
·
|
the
impact of an intensely competitive lipid-lowering market with competition
from multi-source generic simvastatin and branded products in the
U.S.;
|
·
|
increased
payer pressure in the U.S.; and
|
·
|
slower
growth in the lipid-lowering market, due in part to a slower rate of
growth in the Medicare Part D population and, reflecting the global
recession, heightened overall patient cost-sensitivity in the U.S. and
adoption of non-prescription treatment options like nutraceuticals and
functional foods;
|
|
partially
offset by:
|
·
|
operating
growth internationally.
|
·
|
Norvasc, for treating
hypertension, lost exclusivity in the U.S. in March 2007. Norvasc has also
experienced patent expirations in most other major markets, with the
exception of Canada, where the amlodipine besylate patent expires in 2010.
Norvasc worldwide revenues in the first quarter of 2009 decreased 6%
compared to the same period in
2008.
|
·
|
Chantix/Champix, the
first new prescription treatment to aid smoking cessation in nearly a
decade, became available to patients in the U.S. in August 2006 and in
select EU markets in December 2006 and has been launched in all major
markets. Chantix/Champix has been prescribed to more than ten million
patients globally since its launch. Chantix/ Champix recorded worldwide
revenues of $177 million in the first quarter of 2009, a decrease of 36%,
compared to the same period in 2008. In the U.S., revenues of $112 million
in the first quarter of 2009 declined 42% compared to the same period in
2008, following changes to the Chantix label in 2008 and other factors.
Internationally, revenues of $65 million in the first quarter of 2009
decreased 22% compared to the same period in 2008, following the label
changes and reflecting the negative impact of foreign exchange, which
decreased revenues by 14%.
|
·
|
Caduet, a single-pill
therapy combining Norvasc and Lipitor, recorded worldwide revenues of $134
million, a decrease of 9% for the first quarter of 2009, compared to the
same period in 2008, primarily due to increased generic competition as
well as an overall decline in U.S. hypertension market
volume.
|
·
|
Lyrica, indicated for
the management of post-herpetic neuralgia (PHN), diabetic peripheral
neuropathy (DPN), and fibromyalgia, and as adjunctive therapy for adult
patients with partial onset seizures in the U.S., and for neuropathic pain
and general anxiety disorder (GAD) outside the U.S., recorded worldwide
revenues of $684 million in the first quarter of 2009, an increase of 17%,
compared to the same period in 2008. Lyrica’s prescription volume in the
U.S. has been adversely affected by increased generic competition
reflecting the global recession. In June 2007, Lyrica was approved in the
U.S. for the management of fibromyalgia, one of the most common chronic
widespread pain conditions, which affects more than five million
Americans. Lyrica is the leading branded agent for neuropathic pain
worldwide and for DPN/PHN and fibromyalgia in the
U.S.
|
·
|
Geodon/Zeldox, a
psychotropic agent, is a dopamine and serotonin receptor antagonist
indicated for the treatment of schizophrenia and acute manic or mixed
episodes associated with bipolar disorder. It is available in both an oral
capsule and rapid-acting intramuscular formulation. In the first quarter
of 2009, Geodon worldwide revenues decreased 5%, compared to the same
period in 2008, due to increased generic competition, slow growth in the
antipsychotic market in the U.S. as well as the unfavorable impact of
foreign exchange. Geodon is supported by Pfizer’s recently launched
psychiatric field force and Geodon’s efficacy and favorable tolerability
and metabolic profiles.
|
·
|
Celebrex, a treatment
for the signs and symptoms of osteoarthritis and rheumatoid arthritis and
acute pain in adults, experienced an 8% decrease in worldwide revenues to
$564 million for the first quarter of 2009, due to increased generic
competition. Celebrex is supported by continued educational and
promotional efforts highlighting its efficacy and safety profile for
appropriate patients.
|
·
|
Zyvox is the world’s
best-selling branded agent for the treatment of certain serious
Gram-positive pathogens, including Methicillin-Resistant
Staphylococcus-Aureus (MRSA). MRSA remains a serious and
growing threat in hospitals and the community. Zyvox is an excellent
first-line choice for the treatment of adults and children with
complicated skin and skin structure infections and nosocomial pneumonia
due to known or suspected MRSA. Zyvox is the only FDA-approved agent for
MRSA that offers intravenous and oral formulations for these indications.
Its unique mechanism of action minimizes the potential for
cross-resistance. To date, more than three million patients have been
treated worldwide. Zyvox worldwide sales grew 9% to $283 million in the
first quarter of 2009.
|
·
|
Selzentry/Celsentri,
(maraviroc tablets), a CCR5 antagonist, is the first in a new class of
oral HIV medicines in more than a decade known as CCR5 antagonists.
Selzentry/Celsentri was approved in the U.S. and Europe in 2007 and in
Japan in 2008, and is indicated for combination anti-retroviral treatment
of treatment-experienced adults infected with only CCR5-tropic HIV-1, who
have evidence of viral replication and have HIV-1 strains resistant to
multiple anti-retroviral agents. A diagnostic test confirms whether a
patient is infected with CCR5-tropic HIV-1, which is also known as
“R5-virus.” On April 16, 2009, we announced that we entered into an
agreement with GSK to form a new, HIV company that will develop and market
our combined portfolio of HIV assets, including Selzentry/Celsentri. (See
the “Our Strategic Initiatives - Strategy and Recent Transactions” section
of this MD&A.)
|
·
|
Viagra remains the
leading treatment for erectile dysfunction and one of the world’s most
recognized pharmaceutical brands after more than a decade. Viagra
worldwide revenues declined 1% to $454 million in the first quarter of
2009 compared to the same period in 2008. In the U.S., revenues of $258
million in the first quarter of 2009 increased 16% compared with the same
period in 2008. Internationally, Viagra revenues of $196 million in the
first quarter of 2009 decreased 18% compared to the same period in 2008
due to the unfavorable impact of foreign exchange, increased competition
and the loss of market exclusivity in a number of countries in
Europe.
|
·
|
Detrol/Detrol LA, a
muscarinic receptor antagonist, is the most prescribed branded medicine
worldwide for overactive bladder. Detrol LA is an extended-release
formulation taken once a day. Detrol/Detrol LA worldwide revenues declined
8% to $289 million in the first quarter of 2009, compared to the same
period in 2008 primarily due to increased competition from other branded
medicines.
|
·
|
Sutent, for the treatment
of advanced renal cell carcinoma, including metastatic renal cell
carcinoma, and gastrointestinal stomach tumors (GIST) after disease
progression on, or intolerance to, imatinib mesylate, was launched in the
U.S. in January 2006. It has now been launched in all major markets,
including Japan, where it was approved in April 2008 for the treatment of
GIST, after failure of imatinib treatment due to resistance, and for renal
cell carcinoma not indicated for curative resection and mRCC. Sutent
recorded worldwide revenues of $202 million in the first quarter of 2009,
an increase of 7% compared to the same period in 2008. We continue to
drive growth in the U.S. and internationally, supported by
cost-effectiveness data and efficacy data in first-line mRCC – including
2-year survival data, which represents the first time overall survival of
two years has been seen in the treatment of advanced kidney cancer, as
well as through the promotion of access and health care coverage. As of
March 29, 2009, Sutent was the best-selling medicine in the world for the
treatment of first-line mRCC.
|
·
|
Camptosar, indicated as
first-line therapy for metastatic colorectal cancer in combination with
5-fluorouracil and leucovorin, lost exclusivity in the U.S. in February
2008. It is also indicated for patients in whom metastatic colorectal
cancer has recurred or progressed following initial fluorouracil-based
therapy. Camptosar is for intravenous use only. Camptosar worldwide
revenues in the first quarter of 2009 decreased 43% to $109 million,
compared to the same period in 2008, primarily as a result of the loss of
exclusivity.
|
·
|
Xalatan, a
prostaglandin, is the world’s leading branded agent to reduce elevated eye
pressure in patients with open-angle glaucoma or ocular hypertension.
Xalatan's proven clinical benefits and studies demonstrating long-term
safety should support the continued growth of this important medicine.
Xalacom, a fixed
combination prostaglandin (Xalatan) and beta blocker (timolol), is
available outside the U.S. Xalatan/Xalacom worldwide revenues were flat in
the first quarter of 2009, compared to the same period in
2008.
|
·
|
Genotropin, the world’s
leading human growth hormone, is used in children for the treatment of
short stature with growth hormone deficiency, Prader-Willi Syndrome,
Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short
Stature (in the U.S. only) and Chronic Renal Insufficiency (outside the
U.S. only), as well as in adults with growth hormone deficiency.
Genotropin is supported by a broad platform of innovative
injection-delivery devices. Genotropin worldwide revenues decreased 4% in
the first quarter of 2009 to $197 million, compared to the same period in
2008 primarily due to the unfavorable impact of foreign
exchange.
|
·
|
Vfend, as the only
branded agent available in intravenous and oral forms, continues to build
on its position as the best selling systemic, antifungal agent worldwide.
Vfend’s overall global sales continue to be driven by its acceptance as an
excellent broad spectrum agent for treating yeast and moulds. In the U.S.,
Vfend’s growth continues to outpace the overall market driven by the oral
form which has gained solid positioning as a step-down agent that
facilitates discharge from the hospital. Vfend recorded
worldwide revenues of $179 million in the first quarter of 2009, an
increase of 5% compared to the same period in 2008. In the U.S., revenues
of $62 million in the first quarter of 2009 increased 18% compared to the
same period in 2008, reflecting solid growth. Internationally,
Vfend revenues were $117 million in the first quarter of 2009, a 1%
decrease compared to the same period in 2008, due to the unfavorable
impact of foreign exchange.
|
First
Quarter
|
||||||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
%
Change
|
|||||||||
Livestock
products
|
$ | 322 | $ | 385 | (16 | ) | ||||||
Companion
animal products
|
215 | 234 | (8 | ) | ||||||||
Total
Animal Health
|
$ | 537 | $ | 619 | (13 | ) |
·
|
the
global recession, which negatively affected global spending on veterinary
care; and
|
·
|
a
planned change in terms with U.S. distributors resulting in an
anticipated, one-time reduction in U.S. distributor
inventories.
|
Product
|
Indication
|
Date
Submitted
|
Selzentry
(maraviroc)
|
HIV
in treatment-naïve patients
|
December
2008
|
Geodon
|
Maintenance
treatment of bipolar mania
|
December
2008
|
Geodon
|
Treatment
of bipolar disorders – Pediatric filing
|
October
2008
|
Fablyn
(lasofoxifene)
|
Treatment
of osteoporosis
|
December
2007
|
Spiriva
|
Respimat
device for chronic obstructive pulmonary disease
|
November
2007
|
Zmax
|
Treatment
of bacterial infections—sustained release—acute otitis
media
(AOM) and sinusitis – Pediatric filing
|
November
2006
|
Vfend
|
Treatment
of fungal infections – Pediatric filing
|
June
2005
|
Thelin
|
Treatment
of pulmonary arterial hypertension (PAH)
|
May
2005
|
Product
|
Description
of Event
|
Date
Approved
|
Date
Submitted
|
Fablyn
(lasofoxifene)
|
Approval
in the EU for the treatment of osteoporosis
|
February
2009
|
––
|
Zithromac
|
Approval
in Japan for bacterial infections
|
January
2009
|
––
|
Celsentri
(maraviroc)
|
Application
submitted in the EU for HIV in treatment-naïve patients
|
––
|
January
2009
|
Geodon
|
Application
submitted in the EU for pediatric bipolar disorders
|
––
|
October
2008
|
Lyrica
|
Application
submitted in Japan for the treatment of pain associated with post-herpetic
neuralgia
|
––
|
May
2008
|
Application
submitted in the EU for the treatment of fibromyalgia
|
––
|
March
2008
|
|
Xalacom
|
Application
submitted in Japan for the treatment of glaucoma
|
––
|
February
2008
|
Caduet
|
Application
submitted in Japan for hypertension
|
––
|
November
2007
|
Celebrex
|
Application
submitted in Japan for treatment of lower-back pain
|
––
|
February
2007
|
Product
|
Indication
|
Celebrex
|
Acute
gouty arthritis
|
Eraxis/Vfend
Combination
|
Aspergillosis
fungal infections
|
Lyrica
|
Epilepsy
monotherapy; post-operative pain; GAD; restless legs
syndrome
|
Macugen
|
Diabetic
macular edema
|
Revatio
|
Pediatric
pulmonary arterial hypertension
|
Sutent
|
Breast
cancer; colorectal cancer; non-small cell lung cancer; prostate cancer;
liver cancer
|
Zithromax/chloroquine
|
Malaria
|
·
|
savings
related to our cost-reduction
initiatives;
|
·
|
the
favorable impact of foreign exchange on expenses;
and
|
·
|
the
impact of lower implementation costs associated with our cost-reduction
initiatives of $76 million in the first quarter of 2009, compared to $138
million in the first quarter of
2008.
|
·
|
savings
related to our cost-reduction
initiatives;
|
·
|
the
favorable impact of foreign exchange on
expenses;
|
·
|
the
impact of lower implementation costs associated with our cost-reduction
initiatives of $46 million in the first quarter of 2009, compared to $75
million in the first quarter of 2008;
and
|
·
|
certain
insurance recoveries of $165 million related to legal-defense
costs.
|
·
|
savings
related to our cost-reduction
initiatives;
|
·
|
the
favorable impact of foreign exchange on expenses;
and
|
·
|
the
impact of lower implementation costs associated with our cost-reduction
initiatives of $41 million in the first quarter of 2009, compared to $146
million in the first quarter of
2008;
|
·
|
a
$150 million milestone payment to BMS recorded in the first quarter of
2009 in connection with the collaboration on
apixaban.
|
First
Quarter
|
||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||
Implementation
costs(a)
|
$ | 174 | $ | 357 | ||||
Restructuring
charges(b)
|
157 | 178 | ||||||
Total
costs related to our cost-reduction initiatives
|
$ | 331 | $ | 535 |
(a)
|
For
the first quarter of 2009, included in Cost of sales ($76
million), Selling, informational and
administrative expenses ($46 million), Research and development
expenses ($41 million) and Other (income)/deductions -
net ($11 million). For the first quarter of 2008, included in Cost of sales ($138
million), Selling,
informational and administrative expenses ($75 million), Research and development
expenses ($146 million) and Other (income)/deductions –
net ($2 million income).
|
(b)
|
Included in Restructuring charges and acquisition-related costs. |
First
Quarter
|
||||
(millions
of dollars)
|
Mar.
29,
2009
|
|||
Transaction
costs(a)
|
$ | 369 | ||
Pre-integration
costs and other(b)
|
28 | |||
Total
acquisition-related costs(c)
|
$ | 397 |
(a)
|
Transaction
costs include banking, legal, accounting and other costs directly related
to our pending acquisition of Wyeth. Substantially all of the costs
incurred to date are fees related to our $22.5 billion bridge credit
agreement entered into with financial institutions on March 12, 2009 (see
Notes to Condensed Consolidated Financial Statements - Note 8C. Financial
Instruments: Long-Term Debt) to partially fund our pending
acquisition of Wyeth. Upon our issuance of $13.5 billion of senior
unsecured notes on March 24, 2009, the commitment under the bridge credit
agreement was reduced by an amount equal to the net proceeds we received
from such issuance, to a current balance of $9.1 billion, and,
accordingly, we expensed the portion of the bridge credit agreement fees
associated with the $13.5 billion
reduction.
|
(b)
|
Pre-integration
costs represent external, incremental costs directly related to our
pending acquisition of Wyeth and include costs associated with preparing
for systems and other integration
activities.
|
(c)
|
Included
in Restructuring charges
and acquisition-related
costs.
|
·
|
Senior
management receives a monthly analysis of our operating results that is
prepared on an Adjusted income
basis;
|
·
|
Our
annual budgets are prepared on an Adjusted income basis;
and
|
·
|
Senior
management’s annual compensation is derived, in part, using this Adjusted
income measure. Adjusted income is one of the performance metrics utilized
in the determination of bonuses under the Pfizer Inc. Executive Annual
Incentive Plan that is designed to limit the bonuses payable to the
Executive Leadership Team (ELT) for purposes of Internal Revenue Code
Section 162(m). Subject to the Section 162(m) limitation, the bonuses are
funded from a pool based on the achievement of three financial metrics,
including adjusted diluted earnings per share, which is derived from
Adjusted income. These metrics derived from Adjusted income account for
(i) 17% of the target bonus for ELT members and (ii) 33% of the bonus pool
made available to ELT members and other members of senior
management.
|
First
Quarter
|
||||||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
%
Incr./
(Decr.)
|
|||||||||
Reported
net income attributable to Pfizer Inc.
|
$ | 2,729 | $ | 2,784 | (2 | ) | ||||||
Purchase
accounting adjustments - net of tax
|
354 | 934 | (62 | ) | ||||||||
Acquisition-related
costs - net of tax
|
252 | 1 | 251 | |||||||||
Discontinued
operations - net of tax
|
(1 | ) | 4 | * | ||||||||
Certain
significant items - net of tax
|
333 | 376 | (11 | ) | ||||||||
Adjusted
income
|
$ | 3,667 | $ | 4,099 | (11 | ) |
First
Quarter
|
||||||||
(millions
of dollars)
|
Mar.
29,
2009
|
Mar.
30,
2008
|
||||||
Purchase
accounting adjustments:
|
||||||||
Intangible amortization and
other(a)
|
$ | 546 | $ | 758 | ||||
In-process research and
development charges(b)
|
– | 398 | ||||||
Total purchase accounting
adjustments, pre-tax
|
546 | 1,156 | ||||||
Income taxes
|
(192 | ) | (222 | ) | ||||
Total purchase accounting
adjustments - net of tax
|
354 | 934 | ||||||
Acquisition-related
costs:
|
||||||||
Transaction costs(c)
|
369 | – | ||||||
Pre-integration costs and
other(c)
|
28 | 1 | ||||||
Total acquisition-related costs,
pre-tax
|
397 | 1 | ||||||
Income taxes
|
(145 | ) | – | |||||
Total acquisition-related costs -
net of tax
|
252 | 1 | ||||||
Discontinued
operations:
|
||||||||
Total discontinued operations -
net of tax
|
(1 | ) | 4 | |||||
Certain
significant items:
|
||||||||
Restructuring charges –
cost-reduction initiatives(c)
|
157 | 177 | ||||||
Implementation costs –
cost-reduction initiatives(d)
|
174 | 357 | ||||||
Certain legal matters(e)
|
132 | – | ||||||
Other
|
10 | 7 | ||||||
Total certain significant items,
pre-tax
|
473 | 541 | ||||||
Income taxes
|
(140 | ) | (165 | ) | ||||
Total certain significant items -
net of tax
|
333 | 376 | ||||||
Total
purchase accounting adjustments, acquisition-related
costs, discontinued operations and
certain significant
items - net of tax
|
$ | 938 | $ | 1,315 |
(a)
|
Included
primarily in Amortization of intangible
assets.
|
(b)
|
As
required through December 31, 2008, included in Acquisition-related in-process
research and development charges, primarily related to our
acquisitions of CovX, Coley and two smaller acquisitions related to Animal
Health in the first quarter of 2008. As a result of adopting Financial
Accounting Standards Board Statement of Financial Accounting Standards No.
141R, Business
Combinations, as amended, beginning January 1, 2009, IPR&D
related to future acquisitions will be recorded on our consolidated
balance sheet as indefinite-lived intangible assets. We made no
acquisitions in the first quarter of
2009.
|
(c)
|
Included
in Restructuring charges
and acquisition-related
costs.
|
(d)
|
For
the first quarter of 2009, included in Cost of sales ($76
million), Selling,
informational and administrative expenses ($46 million), Research and development
expenses ($41 million) and Other (income)/deductions -
net ($11 million). For the first quarter of 2008, included in Cost of sales ($138
million), Selling,
informational and administrative expenses ($75 million), Research and development
expenses ($146 million) and Other (income)/deductions -
net ($2 million income).
|
(e)
|
Included
in Other
(income)/deductions - net.
|
(millions
of dollars)
|
Mar.
29,
2009
|
Dec.
31,
2008
|
||||||
Financial
assets:
|
||||||||
Cash and cash
equivalents
|
$ | 1,247 | $ | 2,122 | ||||
Short-term
investments
|
32,805 | 21,609 | ||||||
Short-term loans
|
793 | 824 | ||||||
Long-term investments and
loans
|
13,536 | 11,478 | ||||||
Total
financial assets
|
48,381 | 36,033 | ||||||
Debt:
|
||||||||
Short-term borrowings, including
current portion of long-term debt
|
7,613 | 9,320 | ||||||
Long-term debt
|
21,064 | 7,963 | ||||||
Total
debt
|
28,677 | 17,283 | ||||||
Net
financial assets
|
$ | 19,704 | $ | 18,750 |
Long-Term-Debt
|
Date
of
Last
Action
|
|||
Name
of Rating Agency
|
Commercial
Paper
|
Rating
|
Outlook
|
|
Moody’s
|
P-1
|
Aa2
|
Negative
|
March
2009
|
S&P
|
A1+
|
AAA
|
Negative
|
December
2006
|
(millions
of dollars, except ratios and per common share data)
|
Mar.
29,
2009
|
Dec.
31,
2008
|
||||||
Cash
and cash equivalents and short-term investments and loans
|
$ | 34,845 | $ | 24,555 | ||||
Working
capital(a)
|
$ | 30,913 | $ | 16,067 | ||||
Ratio
of current assets to current liabilities
|
2.32:1
|
1.59:1
|
||||||
Shareholders’
equity per common share(b)
|
$ | 8.96 | $ | 8.56 |
(a)
|
Working
capital includes assets held for sale of $299 million as of March 29,
2009, and $148 million as of December 31,
2008.
|
(b)
|
Represents
total shareholders’ equity divided by the actual number of common shares
outstanding (which excludes treasury shares and shares held by our
employee benefit trust).
|
·
|
the
timing of receipts and payments in the ordinary course of
business.
|
·
|
net
purchases of investments of $13.6 billion in the first quarter of 2009
primarily reflecting the investment of proceeds from our issuance of $13.5
billion of senior unsecured notes compared to $4.3 billion in the same
period in 2008.
|
·
|
net
borrowings of $11.8 billion in the first quarter of 2009 primarily
reflecting the proceeds from our issuance of $13.5 billion of senior
unsecured notes compared to $3.0 billion in the same period in
2008.
|
Full-Year
2009 Guidance
|
|||||||
($ billions, except per share
amounts)
|
Net
Income(a)
|
Diluted
EPS(a)
|
|||||
Adjusted
income/diluted EPS(b)
guidance
|
~$12.5-$13.2
|
~$1.85-$1.95
|
|||||
Purchase
accounting impacts of business-development transactions completed as of
12/31/08
|
(1.5)
|
(0.23)
|
|||||
Costs
related to cost-reduction initiatives
|
(1.3-1.6)
|
(0.20-0.23)
|
|||||
Wyeth
acquisition-related costs
|
(1.1-1.2)
|
(0.16-0.18)
|
|||||
Certain
legal matters
|
(.1)
|
(0.01)
|
|||||
Reported
Net income attributable to Pfizer Inc./diluted EPS attributable to Pfizer
Inc. common shareholders guidance
|
~$8.1-$9.2
|
~$1.20-$1.35
|
(a)
|
Does
not assume the completion of any business-development transactions not
completed as of March 29, 2009, and excludes the potential effects of
litigation-related matters not substantially resolved as of March 29,
2009, as we do not forecast those matters. However, full-year 2009
financial guidance for reported net income attributable to Pfizer Inc. and
reported diluted EPS attributable to Pfizer Inc. common shareholders do
reflect certain costs incurred, and expected to be incurred, in connection
with the pending Wyeth acquisition, including, but not limited to,
transaction costs, pre-integration costs and financing
costs.
|
(b)
|
For
an understanding of Adjusted income, see the “Adjusted Income” section of
this MD&A.
|
·
|
Success
of research and development
activities;
|
·
|
Decisions
by regulatory authorities regarding whether and when to approve our drug
applications, as well as their decisions regarding labeling and other
matters that could affect the availability or commercial potential of our
products;
|
·
|
Speed
with which regulatory authorizations, pricing approvals and product
launches may be achieved;
|
·
|
Success
of external business-development
activities;
|
·
|
Competitive
developments, including those with respect to competitor drugs and drug
candidates that treat diseases and conditions similar to those treated by
our in-line drugs and drug
candidates;
|
·
|
Ability
to successfully market both new and existing products domestically and
internationally;
|
·
|
Difficulties
or delays in manufacturing;
|
·
|
Trade
buying patterns;
|
·
|
Ability
to meet generic and branded competition after the loss of patent
protection for our products and competitor
products;
|
·
|
Impact
of existing and future legislation and regulatory provisions on product
exclusivity;
|
·
|
Trends
toward managed care and healthcare cost
containment;
|
·
|
U.S.
legislation or regulatory action affecting, among other things,
pharmaceutical product pricing, reimbursement or access, including under
Medicaid, Medicare and other publicly funded or subsidized health
programs; the importation of prescription drugs from outside the U.S. at
prices that are regulated by governments of various foreign countries;
direct-to-consumer advertising and interactions with healthcare
professionals; and the use of comparative effectiveness methodologies that
could be implemented in a manner that focuses primarily on the cost
differences and minimizes the therapeutic differences among pharmaceutical
products and restricts access to innovative
medicines;
|
·
|
Impact
of the Medicare Prescription Drug, Improvement, and Modernization Act of
2003;
|
·
|
Legislation
or regulatory action in markets outside the U.S. affecting pharmaceutical
product pricing, reimbursement or
access;
|
·
|
Contingencies
related to actual or alleged environmental
contamination;
|
·
|
Claims
and concerns that may arise regarding the safety or efficacy of in-line
products and product candidates;
|
·
|
Significant
breakdown, infiltration or interruption of our information technology
systems and infrastructure;
|
·
|
Legal
defense costs, insurance expenses, settlement costs and the risk of an
adverse decision or settlement related to product liability, patent
protection, governmental investigations, ongoing efforts to explore
various means for resolving asbestos litigation, and other legal
proceedings;
|
·
|
Ability
to protect our patents and other intellectual property both domestically
and internationally;
|
·
|
Interest
rate and foreign currency exchange rate
fluctuations;
|
·
|
Governmental
laws and regulations affecting domestic and foreign operations, including
tax obligations;
|
·
|
Changes
in U.S. generally accepted accounting
principles;
|
·
|
Uncertainties
related to general economic, political, business, industry, regulatory and
market conditions including, without limitation, uncertainties related to
the impact on us, our lenders, our customers, our suppliers and
counterparties to our foreign-exchange and interest-rate agreements of the
global recession and recent and possible future changes in global
financial markets;
|
·
|
Any
changes in business, political and economic conditions due to actual or
threatened terrorist activity in the U.S. and other parts of the world,
and related U.S. military action
overseas;
|
·
|
Growth
in costs and expenses;
|
·
|
Changes
in our product, segment and geographic
mix;
|
·
|
Our
ability and Wyeth’s ability to satisfy the conditions to closing our
merger agreement; and
|
·
|
Impact
of acquisitions, divestitures, restructurings, product withdrawals and
other unusual items, including our ability to realize the projected
benefits of our pending acquisition of Wyeth and of our cost-reduction
initiatives.
|
Period
|
Total
Number of
Shares
Purchased(b)
|
Average
Price
Paid
per Share(b)
|
Total
Number of Shares Purchased as Part of Publicly Announced Plan(a)
|
Approximate
Dollar
Value
of Shares That
May
Yet Be Purchased Under the Plan(a)
|
||||||||||||
January
1, 2009, through
January
31, 2009
|
17,104 |
$
|
17.44 | –– |
$
|
5,033,723,296 | ||||||||||
February
1, 2009, through
February
28, 2009
|
246,173 |
$
|
14.71 | –– |
$
|
5,033,723,296 | ||||||||||
March
1, 2009, through
March
29, 2009
|
2,022,781 |
$
|
13.16 | –– |
$
|
5,033,723,296 | ||||||||||
Total
|
2,286,058 |
$
|
13.36 | –– |
(a)
|
On
June 23, 2005, we announced that the Board of Directors authorized a $5
billion share-purchase plan (the “2005 Stock Purchase Plan”). On June 26,
2006, we announced that the Board of Directors increased the authorized
amount of shares to be purchased under the 2005 Stock Purchase Plan from
$5 billion to $18 billion. On January 23, 2008, we announced that the
Board of Directors had authorized a new $5 billion share-purchase plan to
be utilized from time to time. On January 26, 2009, we announced that we
entered into a definitive merger agreement under which we will acquire
Wyeth in a cash-and-stock transaction. The merger agreement limits our
stock purchases to a maximum of $500 million prior to the completion of
the transaction without Wyeth’s consent. The bridge credit agreement
limits our stock purchases and redemptions to a maximum of $250 million
until the commitment expires or is terminated and all loans under the
agreement, if any, have been paid.
|
(b)
|
These
columns reflect the following transactions during the fiscal first quarter
of 2009: (i) the surrender to Pfizer of 1,355,317 shares of common stock
to satisfy tax withholding obligations in connection with the vesting of
restricted stock and restricted stock units issued to employees, and (ii)
the surrender to Pfizer of 930,741 shares of common stock to satisfy tax
withholding obligations in connection with the vesting of
performance-contingent share awards issued to
employees.
|
1.
|
the
election of 14 directors to terms ending in 2010
|
2.
|
a
proposal to ratify the appointment of KPMG LLP as independent registered
public accounting firm for 2009
|
3.
|
approval
of the Pfizer Inc. 2004 Stock Plan, as amended and
restated
|
4.
|
a
shareholder proposal regarding stock options
|
5.
|
a
shareholder proposal regarding an advisory vote on executive
compensation
|
6.
|
a
shareholder proposal regarding cumulative voting
|
7.
|
a
shareholder proposal regarding special shareholder
meetings
|
Nominee
|
Votes
For
|
Votes
Against
|
Abstentions
|
Dennis
A. Ausiello
|
5,201,941,232
|
308,751,860
|
55,436,790
|
Michael
S. Brown
|
5,169,482,271
|
340,577,108
|
56,070,503
|
M.
Anthony Burns
|
5,295,735,762
|
212,774,071
|
57,620,049
|
Robert
N. Burt
|
5,314,113,752
|
196,587,043
|
55,429,087
|
W.
Don Cornwell
|
5,103,262,059
|
406,471,929
|
56,395,894
|
William
H. Gray III
|
5,234,292,957
|
275,099,348
|
56,737,577
|
Constance
J. Horner
|
5,297,372,751
|
213,198,572
|
55,558,559
|
James
M. Kilts
|
5,317,414,134
|
193,839,720
|
54,876,028
|
Jeffrey
B. Kindler
|
5,241,672,193
|
268,976,411
|
55,481,278
|
George
A. Lorch
|
5,305,923,413
|
204,102,707
|
56,103,762
|
Dana
G. Mead
|
5,289,798,672
|
220,216,581
|
56,114,629
|
Suzanne
Nora Johnson
|
5,326,586,335
|
187,016,149
|
52,527,398
|
Stephen
W. Sanger
|
5,338,458,344
|
172,943,405
|
54,728,133
|
William
C. Steere, Jr.
|
5,223,460,981
|
288,223,733
|
54,445,168
|
•
|
5,396,191,550
|
Votes
for approval
|
•
|
142,934,333
|
Votes
against
|
•
|
27,003,999
|
Abstentions
|
•
|
There were no broker non-votes
for this item.
|
•
|
3,980,633,127
|
Votes
for approval
|
•
|
461,873,577
|
Votes
against
|
•
|
36,094,349
|
Abstentions
|
•
|
1,087,528,829
|
Broker
non-votes
|
•
|
265,487,403
|
Votes
for approval
|
•
|
4,171,333,834
|
Votes
against
|
•
|
41,739,241
|
Abstentions
|
•
|
1,087,569,404
|
Broker
non-votes
|
•
|
2,227,207,105
|
Votes
for approval
|
•
|
2,023,711,784
|
Votes
against
|
•
|
227,643,569
|
Abstentions
|
•
|
1,087,567,424
|
Broker
non-votes
|
•
|
1,661,553,030
|
Votes
for approval
|
•
|
2,777,743,690
|
Votes
against
|
•
|
39,316,323
|
Abstentions
|
•
|
1,087,516,839
|
Broker
non-votes
|
•
|
2,283,037,913
|
Votes
for approval
|
•
|
2,152,978,799
|
Votes
against
|
•
|
42,596,331
|
Abstentions
|
•
|
1,087,516,839
|
Broker
non-votes
|
1) Exhibit 10.1 |
-
|
Amendment
No. 2 dated as of May 5, 2009, to the 364-Day Bridge Term Loan Credit
Agreement, dated
as
of March 12, 2009, among Pfizer Inc., the institutions from time to time
party thereto as Lenders and
JPMorgan
Chase Bank, N.A., in its capacity as administrative agent for the
Lenders.
|
|
2)
Exhibit 12
|
-
|
Computation
of Ratio of Earnings to Fixed Charges
|
|
3)
Exhibit 15
|
-
|
Accountants’
Acknowledgement
|
|
4)
Exhibit 31.1
|
-
|
Certification
by the Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
5)
Exhibit 31.2
|
-
|
Certification
by the Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley
Act of 2002
|
|
6)
Exhibit 32.1
|
-
|
Certification
by the Chief Executive Officer Pursuant to 18 U.S.C. Section
1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
|
7)
Exhibit 32.2
|
-
|
Certification
by the Chief Financial Officer Pursuant to 18 U.S.C. Section
1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
Pfizer
Inc.
|
|
(Registrant)
|
|
Dated: May
8, 2009
|
/s/
Loretta V. Cangialosi
|
Loretta
V. Cangialosi, Senior Vice President and
Controller
(Principal
Accounting Officer and
Duly
Authorized Officer)
|